Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1500 participants
OBSERVATIONAL
2010-01-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Epidemiological research is needed to develop a framework to combat this major health problem, by better characterization of the population of men and women at risk and patients with early disease, by better understanding which factors modifiable through health interventions are related to health perception (health-related quality of life) and disease evolution.
This will be possible through a nationwide study, the Canadian Cohort Obstructive Lung disease (CanCOLD), a prospective longitudinal study. The CanCOLD study is built on the current ongoing prevalence nationwide study, the Canadian Obstructive Lung disease "COLD" study.
The CanCOLD will be the first study to assess prevalence of disease across Canada and its consequence in men and women, and to evaluate a conceptual model of disease severity based on patient's health perception (health-related quality of life). Ultimately, this project will extend to a longitudinal follow up (3 years or beyond) and will allow to have a better understanding of the lifestyle risk factors, not only smoking but also diet, physical activity, and co morbid conditions. This will be a great asset to shift from management of a single risk factor (tobacco control) to total COPD risk management. The results of the study will greatly help to assist decision makers in developing policies to improve the diagnosis, the management of COPD and to optimize health care services use.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data
NCT04966637
Canadian Cohort on the Origin and Progression of Airway Disease: Physiology Platform
NCT02153684
Chronic Obstructive Pulmonary Disease Biomarker Study
NCT02050022
The Mixed Phenotype of Asthma and COPD: the Overlap Syndrome
NCT03817333
Markers for Chronic Obstructive Pulmonary Disease (COPD)
NCT00180622
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC\<0.70 and FEV1\<80% of pred.)
No interventions assigned to this group
Group 2
COPD mild (GOLD1)(post-BD FEV1/FVC\<0.70 AND FEV1\>=80% of pred.)
No interventions assigned to this group
Group 3
COPD at risk (ever smoker with post-BD FEV1/FVC\>=0.70)
No interventions assigned to this group
Group 4
"Healthy control" never smokers without respiratory disease (post-BD FEV1/FVC\>=0.70.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All the subjects have taken part in the COLD study, a true population based prevalence study. Subjects must have an inclusion criteria of 40 years and older to participate in the COLD study.
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
GlaxoSmithKline
INDUSTRY
AstraZeneca
INDUSTRY
Pfizer
INDUSTRY
Boehringer Ingelheim
INDUSTRY
Novartis
INDUSTRY
Takeda
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Almirall, SAS
INDUSTRY
McGill University Health Centre/Research Institute of the McGill University Health Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jean Bourbeau
MD, M.Sc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Bourbeau, M.D., M.Sc.
Role: PRINCIPAL_INVESTIGATOR
McGill University Health Centre/Research Institute of the McGill University Health Centre
Wan Tan, M.D.
Role: PRINCIPAL_INVESTIGATOR
CAAA University of British Columbia
François Maltais, M.D.
Role: PRINCIPAL_INVESTIGATOR
CFBA Université Laval
Shawn Aaron, M.D., M.Sc.
Role: PRINCIPAL_INVESTIGATOR
OHGC Ottawa Hospital General Campus
Denis O'Donnell, M.D.
Role: PRINCIPAL_INVESTIGATOR
CEDA Queen's University (Kinsgston)
Darcy D Marciniuk, M.D.
Role: PRINCIPAL_INVESTIGATOR
CCAA University of Saskatchewan
Robert Cowie, M.D.
Role: PRINCIPAL_INVESTIGATOR
CBBA University of Calgary
Kenneth R. Chapman, M.D., M.Sc.
Role: PRINCIPAL_INVESTIGATOR
CEAA University of Toronto
Paul Hernandez, M.D.
Role: PRINCIPAL_INVESTIGATOR
CHAA Dalhousie University (Nova Scotia)
Mark J. FitzGerald, M.D.
Role: PRINCIPAL_INVESTIGATOR
CAAA University of British Columbia
Donald Sin, M.D.
Role: PRINCIPAL_INVESTIGATOR
CAAA University of British Columbia
Andrea Benedetti, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
INUD McGill University Healty Center
Yves Lacasse, M.D., M.Sc.
Role: PRINCIPAL_INVESTIGATOR
CPVR Institut universitaire de cardiologie et de pneumologie de Québec
Pierre Ernst, M.D.
Role: PRINCIPAL_INVESTIGATOR
McGill University
Harvey Coxson, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Roger Goldstein, M.D.
Role: PRINCIPAL_INVESTIGATOR
CEAA University of Toronto
Carlo Marra, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
CAAA University of British Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Health Sciences Centre
Calgary, Alberta, Canada
St-Paul's Hospital
Vancouver, British Columbia, Canada
Halifax Infirmary
Halifax, Nova Scotia, Canada
Kingston General Hospital
Kingston, Ontario, Canada
Ottawa Hospital General
Ottawa, Ontario, Canada
University of Toronto
Toronto, Ontario, Canada
Montreal Chest Institute
Montreal, Quebec, Canada
Royal University Hospital
Saskatoon, Saskatchewan, Canada
Institut universitaire de cardiologie et de pneumologie de Québec
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cordero AIH, Li X, Yang CX, Ambalavanan A, MacIsaac JL, Kobor MS, Doiron D, Tan W, Bourbeau J, Sin DD, Duan Q, Leung JM; CanCOLD Collaborative Research Group. Cannabis smoking is associated with persistent epigenome-wide disruptions despite smoking cessation. BMC Pulm Med. 2025 Apr 9;25(1):168. doi: 10.1186/s12890-025-03634-9.
Ekstrom M, Lewthwaite H, Li PZ, Bourbeau J, Tan WC, Jensen D; CanCOLD Collaborative Research Group. Identifying Abnormal Exertional Breathlessness in COPD: Comparing Modified Medical Research Council and COPD Assessment Test With Cardiopulmonary Exercise Testing. Chest. 2025 Mar;167(3):697-711. doi: 10.1016/j.chest.2024.10.027. Epub 2024 Oct 28.
Virdee S, Tan WC, Hogg JC, Bourbeau J, Hague CJ, Kirby M; CanCOLD Collaborative Research Group. CT Chest Imaging Using Normalized Join-Count: Predicting Emphysema Progression in the CanCOLD Study. Radiology. 2024 Jul;312(1):e233265. doi: 10.1148/radiol.233265.
Phillips DB, James MD, Vincent SG, Elbehairy AF, Neder JA, Kirby M, Ora J, Day AG, Tan WC, Bourbeau J, O'Donnell DE; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Physiological Characterization of Preserved Ratio Impaired Spirometry in the CanCOLD Study: Implications for Exertional Dyspnea and Exercise Intolerance. Am J Respir Crit Care Med. 2024 Jun 1;209(11):1314-1327. doi: 10.1164/rccm.202307-1184OC.
Abozid H, Kirby M, Nasir N, Hartl S, Breyer-Kohansal R, Breyer MK, Burghuber OC, Bourbeau J, Wouters EFM, Tan W; CanCOLD Collaborative research Group and the Canadian Respiratory Research Network. CT airway remodelling and chronic cough. BMJ Open Respir Res. 2023 May;10(1):e001462. doi: 10.1136/bmjresp-2022-001462.
Ross BA, Doiron D, Benedetti A, Aaron SD, Chapman K, Hernandez P, Maltais F, Marciniuk D, O'Donnell DE, Sin DD, Walker BL, Tan W, Bourbeau J; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Short-term air pollution exposure and exacerbation events in mild to moderate COPD: a case-crossover study within the CanCOLD cohort. Thorax. 2023 Oct;78(10):974-982. doi: 10.1136/thorax-2022-219619. Epub 2023 May 5.
Krishnan S, Tan WC, Farias R, Aaron SD, Benedetti A, Chapman KR, Hernandez P, Maltais F, Marciniuk DD, O'Donnell DE, Sin DD, Walker B, Bourbeau J; Canadian Cohort Obstructive Lung Disease Collaborative Research Group and the Canadian Respiratory Research Network. Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease: A Canadian Cohort Study. Chest. 2023 Sep;164(3):637-649. doi: 10.1016/j.chest.2023.02.045. Epub 2023 Mar 4.
Moslemi A, Makimoto K, Tan WC, Bourbeau J, Hogg JC, Coxson HO, Kirby M; Canadian Cohort of Obstructive Lung Disease. Quantitative CT Lung Imaging and Machine Learning Improves Prediction of Emergency Room Visits and Hospitalizations in COPD. Acad Radiol. 2023 Apr;30(4):707-716. doi: 10.1016/j.acra.2022.05.009. Epub 2022 Jun 8.
Phillips DB, Elbehairy AF, James MD, Vincent SG, Milne KM, de-Torres JP, Neder JA, Kirby M, Jensen D, Stickland MK, Guenette JA, Smith BM, Aaron SD, Tan WC, Bourbeau J, O'Donnell DE; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease: Results from the CanCOLD Study. Am J Respir Crit Care Med. 2022 Jun 15;205(12):1391-1402. doi: 10.1164/rccm.202109-2171OC.
Tan WC, Bourbeau J, Nadeau G, Wang W, Barnes N, Landis SH, Kirby M, Hogg JC, Sin DD; CanCOLD Collaborative Research Group; authors would also like to thank the men and women who participated in the study and individuals in the CanCOLD Collaborative Research Group not listed as authors:. High eosinophil counts predict decline in FEV1: results from the CanCOLD study. Eur Respir J. 2021 May 27;57(5):2000838. doi: 10.1183/13993003.00838-2020. Print 2021 May.
Lewthwaite H, Elsewify O, Niro F, Bourbeau J, Guenette JA, Maltais F, Marciniuk DD, O'Donnell DE, Smith BM, Stickland MK, Tan WC, Jensen D; CanCOLD Collaborative Research Group; Canadian Respiratory Research Network. Normative Cardiopulmonary Exercise Test Responses at the Ventilatory Threshold in Canadian Adults 40 to 80 Years of Age. Chest. 2021 May;159(5):1922-1933. doi: 10.1016/j.chest.2020.11.009. Epub 2020 Nov 18.
Barrecheguren M, Pinto L, Mostafavi-Pour-Manshadi SM, Tan WC, Li PZ, Aaron SD, Benedetti A, Chapman KR, Walker B, Fitzgerald JM, Hernandez P, Maltais F, Marciniuk DD, O'Donnell DE, Sin DD, Bourbeau J; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Identification and definition of asthma-COPD overlap: The CanCOLD study. Respirology. 2020 Aug;25(8):836-849. doi: 10.1111/resp.13780. Epub 2020 Feb 16.
Gupta N, Pinto L, Benedetti A, Li PZ, Tan WC, Aaron SD, Chapman KR, FitzGerald JM, Hernandez P, Marciniuk DD, Maltais F, O'Donnell DE, Sin D, Walker BL, Bourbeau J; Canadian Respiratory Research Network and the CanCOLD Collaborative Research Group. The COPD Assessment Test: Can It Discriminate Across COPD Subpopulations? Chest. 2016 Nov;150(5):1069-1079. doi: 10.1016/j.chest.2016.06.016. Epub 2016 Jun 27.
Tan WC, Sin DD, Bourbeau J, Hernandez P, Chapman KR, Cowie R, FitzGerald JM, Marciniuk DD, Maltais F, Buist AS, Road J, Hogg JC, Kirby M, Coxson H, Hague C, Leipsic J, O'Donnell DE, Aaron SD; CanCOLD Collaborative Research Group. Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. Thorax. 2015 Sep;70(9):822-9. doi: 10.1136/thoraxjnl-2015-206938. Epub 2015 Jun 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRO-93326
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.